Sum­mit shares shoot up on pos­i­tive DMD PhII; As­traZeneca and al­lies back a new in­cu­ba­tor/ac­cel­er­a­tor at Babra­ham

→ Shares of Ox­ford-based Sum­mit Ther­a­peu­tics $SMMT shot up 28% on Thurs­day morn­ing af­ter rolling out pos­i­tive bio­mark­er da­ta from a Phase II study of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.